Port Huron, Michigan Clinical Trials

A listing of Port Huron, Michigan clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 21 clinical trials
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia cells produce a protein called BCR-ABL. The BCR-ABL protein helps chronic myeloid leukemia cells to grow and divide. Tyrosine kinase inhibitors, such as bosutinib, …

Great Lakes Cancer Management Specialists-Doctors Park
 (15.7 away) Contact site
  • 38 views
  • 11 May, 2021
  • +441 other locations
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for …

neuroendocrine tumor
teratoma
serous cystadenocarcinoma
adrenal tumor
prophylaxis
Great Lakes Cancer Management Specialists-Doctors Park
 (15.7 away) Contact site
  • 5957 views
  • 16 Jun, 2021
  • +812 other locations
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, erlotinib hydrochloride, and gemcitabine work in different ways to stop the growth …

lung cancer
measurable disease
erlotinib
metastasis
cancer
McLaren Cancer Institute-Macomb
 (34.7 away) Contact site
  • 238 views
  • 06 Jun, 2021
  • +193 other locations
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 …

body mass index
diabetes
overweight or obesity
Bluewater Clinical Research
 (3.8 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +21 other locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic …

brain tumor
corticosteroid
targeted therapy
dolutegravir
gonadotropin releasing hormone
Great Lakes Cancer Management Specialists-Doctors Park
 (15.7 away) Contact site
  • 6087 views
  • 16 Jun, 2021
  • +1016 other locations
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects

This is a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.

nasal congestion
nasal discharge
respiratory syncytial virus infection
wheezing
dyspnea
Bluewater Clinical Research Group
 (3.1 away) Contact site
  • 99 views
  • 14 Jun, 2021
  • +109 other locations
Obinutuzumab With or Without Umbralisib Lenalidomide or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

This phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere …

fludeoxyglucose f-18
lenalidomide
conjugated bilirubin
bendamustine
rituximab
Great Lakes Cancer Management Specialists-Doctors Park
 (15.7 away) Contact site
  • 504 views
  • 16 Jun, 2021
  • +379 other locations
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.

cancer
immunostimulants
primary cancer
Bronson Battle Creek
 (145.1 away) Contact site
  • 90 views
  • 10 Feb, 2021
  • +271 other locations
S1613 Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab …

braf gene
her-2
adjuvant chemotherapy
carcinoma in situ
monoclonal antibodies
Huron Medical Center PC
 (1.4 away) Contact site
  • 419 views
  • 20 May, 2021
  • +829 other locations
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36 -week open-label extension period.

hidradenitis
antiseptics
Investigative Site 004
 (7.6 away) Contact site
  • 35 views
  • 16 Jun, 2021
  • +24 other locations